Phase III German multicenter randomized trial | n = 368 | Resected PDAC | JAMA 2013 **Oettle et al.** Helmut Oettle Published in JAMA, 2013 Enrollment: 1998–2004 Long-term follow-up through 2012 [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/24104372/) --- ### Essential Takeaway CONKO-001 established adjuvant gemcitabine as standard postoperative therapy after PDAC resection by demonstrating major improvements in disease-free survival and durable long-term overall survival compared with observation alone. The trial fundamentally shifted pancreatic cancer management away from surgery-only paradigms and reinforced the systemic nature of PDAC even after curative-intent resection. --- ### Clinical Question Does adjuvant gemcitabine improve outcomes after curative-intent resection of pancreatic ductal adenocarcinoma compared with observation alone? --- ### Population - Resected PDAC - R0 or R1 resections - No prior neoadjuvant therapy At the time of the study, postoperative observation remained common in many centers. --- ### Study Design #### Arm 1 — Adjuvant Gemcitabine - 6 cycles gemcitabine - Surveillance imaging afterward #### Arm 2 — Observation - Surveillance alone Follow-up included: - abdominal ultrasound every 8 weeks - clinical follow-up every 8 weeks for 5 years or until death --- ### Endpoints #### Primary Endpoint Disease-free survival (DFS) #### Secondary Endpoints - Overall survival (OS) - Safety/toxicity --- ### Key Results #### Disease-Free Survival Major improvement with adjuvant gemcitabine: - 13.4 vs 6.7 months - HR 0.55 - p < 0.001 DFS was essentially doubled compared with observation. --- #### Overall Survival ##### Long-Term Survival - 5-year OS: - 20.7% vs 10.4% - 10-year OS: - 12.2% vs 7.7% These findings demonstrated durable long-term benefit from postoperative systemic therapy. --- ### Additional Findings #### Established Systemic Therapy as Essential The study demonstrated that: - surgery alone was insufficient for most patients - occult micrometastatic disease was common - postoperative systemic therapy meaningfully reduced recurrence risk #### Defined the Gemcitabine Era CONKO-001 established gemcitabine as the reference adjuvant backbone for future pancreatic cancer trials for many years. --- ### Interpretation CONKO-001 became one of the most influential trials in pancreatic oncology because it firmly established adjuvant chemotherapy as standard of care after PDAC resection. The study fundamentally changed treatment philosophy by reinforcing that pancreatic cancer behaves as a systemic disease even after apparently curative surgery. It also shifted the field away from observation-only postoperative management and laid the foundation for subsequent modern adjuvant trials. --- ### Important Limitations #### Older Era Trial - Predated modern: - staging - perioperative care - molecular profiling - neoadjuvant strategies #### Observation Control Arm Observation alone would likely be considered unethical today given modern standards. #### Gemcitabine Monotherapy Modern regimens, particularly mFOLFIRINOX, now demonstrate substantially greater efficacy in fit patients. --- ### Practice Impact CONKO-001 established the modern principle that: > medically fit patients with resected PDAC should receive systemic therapy. Although gemcitabine monotherapy has largely been supplanted in fit patients, the trial remains historically foundational and served as the platform upon which later landmark studies were built, including: - ESPAC-4 - PRODIGE-24 - APACT The study remains one of the most important transitions away from surgery-alone management in pancreatic cancer.